FI3220916T3 - Menetelmä syövän hoitoon n-((4,6-dimetyli-2-okso-1,2-dihydropyridin-3-yyli)metyyli)-5-(etyyli(tetrahydro-2h-pyran-4-yyli)amino)- 4-metyyli-4'-(morfolinometyyli)-[1,1'-bifenyyli]-3-karboksamidilla - Google Patents

Menetelmä syövän hoitoon n-((4,6-dimetyli-2-okso-1,2-dihydropyridin-3-yyli)metyyli)-5-(etyyli(tetrahydro-2h-pyran-4-yyli)amino)- 4-metyyli-4'-(morfolinometyyli)-[1,1'-bifenyyli]-3-karboksamidilla Download PDF

Info

Publication number
FI3220916T3
FI3220916T3 FIEP15860676.4T FI15860676T FI3220916T3 FI 3220916 T3 FI3220916 T3 FI 3220916T3 FI 15860676 T FI15860676 T FI 15860676T FI 3220916 T3 FI3220916 T3 FI 3220916T3
Authority
FI
Finland
Prior art keywords
pharmaceutical formulation
dissolution
weight
therapeutic agent
formulation according
Prior art date
Application number
FIEP15860676.4T
Other languages
English (en)
Finnish (fi)
Inventor
Heike Keilhack
Brett Truitt
Yuta Suzuki
Tsukasa Murase
Futoshi Shikata
Original Assignee
Epizyme Inc
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc, Eisai R&D Man Co Ltd filed Critical Epizyme Inc
Application granted granted Critical
Publication of FI3220916T3 publication Critical patent/FI3220916T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
FIEP15860676.4T 2014-11-17 2015-11-17 Menetelmä syövän hoitoon n-((4,6-dimetyli-2-okso-1,2-dihydropyridin-3-yyli)metyyli)-5-(etyyli(tetrahydro-2h-pyran-4-yyli)amino)- 4-metyyli-4'-(morfolinometyyli)-[1,1'-bifenyyli]-3-karboksamidilla FI3220916T3 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462080985P 2014-11-17 2014-11-17
US201562166572P 2015-05-26 2015-05-26
US201562251903P 2015-11-06 2015-11-06
PCT/US2015/061194 WO2016081523A1 (en) 2014-11-17 2015-11-17 Method for treating cancer

Publications (1)

Publication Number Publication Date
FI3220916T3 true FI3220916T3 (fi) 2023-06-19

Family

ID=56014476

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP15860676.4T FI3220916T3 (fi) 2014-11-17 2015-11-17 Menetelmä syövän hoitoon n-((4,6-dimetyli-2-okso-1,2-dihydropyridin-3-yyli)metyyli)-5-(etyyli(tetrahydro-2h-pyran-4-yyli)amino)- 4-metyyli-4'-(morfolinometyyli)-[1,1'-bifenyyli]-3-karboksamidilla

Country Status (21)

Country Link
US (3) US10786511B2 (enExample)
EP (2) EP4272742A1 (enExample)
JP (3) JP6829684B2 (enExample)
KR (3) KR102338802B1 (enExample)
CN (2) CN116650500A (enExample)
AU (3) AU2015350108B2 (enExample)
BR (1) BR112017010166A2 (enExample)
CA (1) CA2967664A1 (enExample)
DK (1) DK3220916T3 (enExample)
EA (1) EA201791095A1 (enExample)
ES (1) ES2947819T3 (enExample)
FI (1) FI3220916T3 (enExample)
HU (1) HUE062159T2 (enExample)
IL (4) IL296080B2 (enExample)
LT (1) LT3220916T (enExample)
MX (2) MX383484B (enExample)
PL (1) PL3220916T3 (enExample)
PT (1) PT3220916T (enExample)
SG (1) SG11201703806XA (enExample)
SI (1) SI3220916T1 (enExample)
WO (1) WO2016081523A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
IL288181B2 (en) 2012-10-15 2024-04-01 Epizyme Inc Methods of treating cancer
CN105873592B (zh) 2013-12-06 2023-01-31 Epizyme股份有限公司 用于治疗癌症的组合疗法
EA038337B1 (ru) 2014-06-17 2021-08-11 Эпизим, Инк. Ингибиторы ezh2 для лечения лимфомы
MX383484B (es) * 2014-11-17 2025-03-11 Epizyme Inc Método para tratar el cáncer.
EP3285773A4 (en) 2015-04-20 2019-04-10 Epizyme, Inc. COMBINATION THERAPY FOR THE TREATMENT OF CANCER
JP6890097B2 (ja) 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
CA2996412A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
JP2019503391A (ja) 2016-01-29 2019-02-07 エピザイム，インコーポレイティド 癌を処置するための併用療法
AU2017273726B2 (en) 2016-06-01 2023-10-19 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
JP2019521988A (ja) 2016-06-17 2019-08-08 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤
AU2018210099A1 (en) 2017-01-19 2019-08-15 Daiichi Sankyo Company, Limited Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
JP2020522687A (ja) 2017-06-02 2020-07-30 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
WO2019050924A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. POLY THERAPY FOR THE TREATMENT OF CANCER
EP4077314A1 (en) * 2019-12-20 2022-10-26 Epizyme, Inc. Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer
JP7628876B2 (ja) 2021-04-23 2025-02-12 日立Astemo株式会社 情報処理装置、情報処理方法、プログラムおよび記憶媒体
WO2023159124A2 (en) * 2022-02-17 2023-08-24 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
AU2023262308A1 (en) 2022-04-27 2024-10-03 Astrazeneca Uk Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119052D0 (en) 1991-09-06 1991-10-23 Boots Co Plc Pharmaceutical compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070026064A1 (en) * 2005-07-29 2007-02-01 Yoder Steven L Pharmaceutical dosage forms having watermark-type identification and authentication inditia
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US8895245B2 (en) 2010-09-10 2014-11-25 Epizyme, Inc. Inhibitors of human EZH2 and methods of use thereof
US20130296325A1 (en) * 2011-01-14 2013-11-07 Bristol-Myers Squibb Company HIGH DRUG LOAD TABLET FORMULATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY]-1-METHYLETHYL ESTER
AU2012223448B2 (en) 2011-02-28 2017-03-16 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
PT2825161T (pt) 2012-03-12 2019-04-29 Epizyme Inc Inibidores de ezh2 humana e métodos de uso dos mesmos
IL308807B2 (en) * 2012-04-13 2025-08-01 Epizyme Inc Combination therapy for treating cancer
HRP20170295T1 (hr) 2012-04-13 2017-04-21 Epizyme, Inc. Oblik soli inhibitora ljudske histonske metiltransferaze ezh2
US10092572B2 (en) 2012-10-15 2018-10-09 Epizyme, Inc. Substituted benzene compounds
IL288181B2 (en) * 2012-10-15 2024-04-01 Epizyme Inc Methods of treating cancer
US20150313906A1 (en) * 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
US9701666B2 (en) 2012-12-21 2017-07-11 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
AU2013361060B2 (en) 2012-12-21 2018-04-19 Epizyme, Inc. 1,4-pyridone compounds
CA2903572A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
WO2014144747A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
LT3057962T (lt) 2013-10-16 2023-12-11 Epizyme, Inc. Hidrochlorido druskos forma, skirta ezh2 inhibavimui
WO2015058125A1 (en) 2013-10-18 2015-04-23 Epizyme, Inc. Method of treating cancer
CN105873592B (zh) 2013-12-06 2023-01-31 Epizyme股份有限公司 用于治疗癌症的组合疗法
EA038337B1 (ru) * 2014-06-17 2021-08-11 Эпизим, Инк. Ингибиторы ezh2 для лечения лимфомы
US20170217941A1 (en) 2014-06-25 2017-08-03 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
SG10201903356XA (en) 2014-10-16 2019-05-30 Epizyme Inc Method for treating cancer
MX383484B (es) * 2014-11-17 2025-03-11 Epizyme Inc Método para tratar el cáncer.
JP6890097B2 (ja) * 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
JP2019521988A (ja) * 2016-06-17 2019-08-08 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤

Also Published As

Publication number Publication date
KR102644844B1 (ko) 2024-03-07
IL296080B1 (en) 2023-08-01
MX383484B (es) 2025-03-11
KR20210156840A (ko) 2021-12-27
DK3220916T3 (da) 2023-06-26
US10786511B2 (en) 2020-09-29
KR102338802B1 (ko) 2021-12-14
SI3220916T1 (sl) 2023-09-29
US20210060030A1 (en) 2021-03-04
PT3220916T (pt) 2023-06-26
EP4272742A1 (en) 2023-11-08
BR112017010166A2 (en) 2018-02-14
IL304252A (en) 2023-09-01
AU2024201171A1 (en) 2024-03-14
CN116650500A (zh) 2023-08-29
AU2021204706A1 (en) 2021-07-29
IL296080A (en) 2022-11-01
NZ731696A (en) 2024-03-22
PL3220916T3 (pl) 2023-08-14
US20170360797A1 (en) 2017-12-21
IL304252B1 (en) 2025-11-01
AU2015350108B2 (en) 2021-04-08
IL252182B2 (en) 2023-02-01
SG11201703806XA (en) 2017-06-29
IL323396A (en) 2025-11-01
CA2967664A1 (en) 2016-05-26
NZ768247A (en) 2024-05-31
JP2023062189A (ja) 2023-05-02
JP2021073241A (ja) 2021-05-13
EP3220916A1 (en) 2017-09-27
EP3220916B1 (en) 2023-04-19
ES2947819T3 (es) 2023-08-21
KR20240035908A (ko) 2024-03-18
US12168014B2 (en) 2024-12-17
LT3220916T (lt) 2023-07-25
MX2017006089A (es) 2017-12-11
AU2015350108A1 (en) 2017-05-25
MX2021006734A (es) 2021-07-02
KR20170103768A (ko) 2017-09-13
IL296080B2 (en) 2023-12-01
JP2017537899A (ja) 2017-12-21
IL252182B (en) 2022-10-01
EA201791095A1 (ru) 2017-10-31
IL252182A0 (en) 2017-07-31
CN107249591B (zh) 2024-01-30
CN107249591A (zh) 2017-10-13
WO2016081523A1 (en) 2016-05-26
US20250064822A1 (en) 2025-02-27
HUE062159T2 (hu) 2023-10-28
EP3220916A4 (en) 2018-07-11
JP7485810B2 (ja) 2024-05-16
JP6829684B2 (ja) 2021-02-10
AU2021204706B2 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
FI3220916T3 (fi) Menetelmä syövän hoitoon n-((4,6-dimetyli-2-okso-1,2-dihydropyridin-3-yyli)metyyli)-5-(etyyli(tetrahydro-2h-pyran-4-yyli)amino)- 4-metyyli-4'-(morfolinometyyli)-[1,1'-bifenyyli]-3-karboksamidilla
AU2022215155B2 (en) Ribociclib tablet
JP2017537899A5 (enExample)
RU2017109139A (ru) Таблетки, содержащие большую дозу рукапариба
ES2654207T3 (es) Composición farmacéutica que contiene fimarsatán e hidroclorotiazida
IL292262B2 (en) Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid
BRPI0608840B1 (pt) composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação
US12350246B2 (en) Eflornithine and sulindac, fixed dose combination formulation
RU2016117186A (ru) Комбинированная композиция, содержащая тадалафил и амлодипин
BR112015021097B1 (pt) Composição farmacêutica sólida compactada em rolo, seu uso e seu processo de fabricação
CN104582684A (zh) 包含5-氯-n-({(5s)-2-氧代-3-[4-(3-氧代-4-吗啉基)苯基]-1,3-噁唑烷-5-基}甲基)-2-噻吩甲酰胺的药物剂型
WO2017075576A1 (en) Eflornithine and sulindac, fixed dose combination formulation
EA202193065A1 (ru) Фармацевтическая композиция, содержащая акситиниб
JP2018536707A5 (enExample)
WO2007004425A1 (ja) 難溶性の有効成分を含有する錠剤
RU2018100755A (ru) Комбинированный препарат мозаприда и рабепразола
JP2020090484A (ja) エルロチニブを有効成分とする医薬錠剤
JP2020075924A (ja) エルロチニブを有効成分とする医薬錠剤
JP6866113B2 (ja) カペシタビンを有効成分とする医薬製剤
JP2014224087A (ja) 光安定性が向上したテルミサルタン含有固形製剤
JP6673798B2 (ja) カペシタビンを有効成分とするフィルムコート医薬製剤
MX2025001991A (es) Composiciones farmaceuticas solidas de adagrasib
NZ731696B2 (en) Method for treating cancer
JP2020075923A (ja) エルロチニブを有効成分とする医薬錠剤
Soujanya Formulation and Evaluation of Oral Disintegrating Tablets of Aripiprazole Solid Dispersions by Sublimation Technique